Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has scheduled its second quarter 2025 earnings conference call for August 7, 2025, at 8:00 a.m. ET. The company will discuss financial results and operational highlights during the call.
Investors can access the call by dialing 1-833-316-0545 (U.S.) or 1-412-317-5726 (international). A live webcast will be available, and a replay will be accessible through Intellia's website after 12 p.m. ET on the same day.
Intellia Therapeutics (NASDAQ:NTLA), azienda in fase clinica specializzata in terapie basate su CRISPR, ha programmato la conferenza telefonica per la presentazione dei risultati del secondo trimestre 2025 per il 7 agosto 2025 alle 8:00 ET. Durante la chiamata verranno discussi i risultati finanziari e gli aspetti operativi.
Gli investitori potranno partecipare chiamando il numero 1-833-316-0545 (USA) o 1-412-317-5726 (internazionale). Sarà disponibile una diretta web e una registrazione sarà accessibile sul sito di Intellia dopo le 12:00 ET dello stesso giorno.
Intellia Therapeutics (NASDAQ:NTLA), una empresa en etapa clínica especializada en terapias basadas en CRISPR, ha programado su conferencia telefónica de resultados del segundo trimestre de 2025 para el 7 de agosto de 2025 a las 8:00 a.m. ET. Durante la llamada se discutirán los resultados financieros y aspectos operativos.
Los inversores pueden acceder llamando al 1-833-316-0545 (EE.UU.) o al 1-412-317-5726 (internacional). Habrá una transmisión en vivo y una repetición estará disponible en el sitio web de Intellia después de las 12 p.m. ET del mismo día.
Intellia Therapeutics (NASDAQ:NTLA)는 CRISPR 기반 치료법을 전문으로 하는 임상 단계 유전자 편집 회사로, 2025년 2분기 실적 발표 컨퍼런스 콜을 2025년 8월 7일 오전 8시 ET에 예정하고 있습니다. 콜에서는 재무 결과와 운영 현황을 논의할 예정입니다.
투자자는 미국 내 1-833-316-0545 또는 해외 1-412-317-5726로 전화하여 참여할 수 있습니다. 실시간 웹캐스트가 제공되며, 같은 날 오후 12시 ET 이후 Intellia 웹사이트에서 다시보기 서비스를 이용할 수 있습니다.
Intellia Therapeutics (NASDAQ:NTLA), une société en phase clinique spécialisée dans les thérapies basées sur CRISPR, a programmé sa conférence téléphonique pour les résultats du deuxième trimestre 2025 le 7 août 2025 à 8h00 ET. La société discutera des résultats financiers et des faits marquants opérationnels lors de l'appel.
Les investisseurs peuvent accéder à l'appel en composant le 1-833-316-0545 (États-Unis) ou le 1-412-317-5726 (international). Un webcast en direct sera disponible et une rediffusion sera accessible sur le site d'Intellia après 12h00 ET le même jour.
Intellia Therapeutics (NASDAQ:NTLA), ein klinisch fortgeschrittenes Unternehmen für Genom-Editing mit Schwerpunkt auf CRISPR-basierten Therapien, hat seine Telefonkonferenz zur Bekanntgabe der Ergebnisse des zweiten Quartals 2025 für den 7. August 2025 um 8:00 Uhr ET angesetzt. Während des Anrufs werden finanzielle Ergebnisse und operative Highlights besprochen.
Investoren können die Konferenz unter der Nummer 1-833-316-0545 (USA) oder 1-412-317-5726 (international) verfolgen. Ein Live-Webcast wird verfügbar sein, und eine Aufzeichnung steht ab 12 Uhr ET am selben Tag auf der Website von Intellia zur Verfügung.
- None.
- None.
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in a conference call on August 7, 2025, at 8 a.m. ET.
To join the call:
- U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
- Please visit this link for a simultaneous live webcast of the call.
A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on August 7, 2025, at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Brittany Chaves
Senior Manager, Investor Relations
brittany.chaves@intelliatx.com
FAQ
When is Intellia Therapeutics (NTLA) Q2 2025 earnings call?
How can investors join Intellia Therapeutics' Q2 2025 earnings call?
Where can I find the replay of Intellia Therapeutics' Q2 2025 earnings call?
What will Intellia Therapeutics discuss in their Q2 2025 earnings call?
